Moleculin Biotech, Inc.

Contributing Author

Recent Articles by Moleculin Biotech, Inc.

Jul-09	Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans MBRX GlobeNewswire
Jun-20	Moleculin Announces $5.9 Million Public Offering MBRX GlobeNewswire
Jun-18	Moleculin Participates in Virtual Investor "What This Means" Segment MBRX GlobeNewswire
Jun-18	Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML MBRX GlobeNewswire
Jun-11	Moleculin Participates in Virtual Investor "What This Means" Segment MBRX GlobeNewswire
Jun-05	Moleculin Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma (STS) Lung Metastases (MB-107) MBRX GlobeNewswire
Jun-04	Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107) MBRX GlobeNewswire
May-14	Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update MBRX GlobeNewswire
May-12	Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial MBRX GlobeNewswire
May-07	Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast MBRX GlobeNewswire
May-06	Moleculin Announces World Health Organization Approval of "naxtarubicin" as International Non-Proprietary Name for Annamycin MBRX GlobeNewswire
May-05	Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents MBRX GlobeNewswire